Dr. Zibelman on Determining Treatments for Patients with RCC

(59)

Dr. Zibelman on Managing Immune-Related Adverse Events

(1:31)

Dr. Zibelman on Combinations of Immunotherapy for RCC

(1:)

Matthew R. Zibelman, MD

(2:32)

Dr. Matthew Zibelman discusses IO Insights Series

(35)

Dr. Matthew Zibelman on IO Institute

(44)

Touring One of the Most Iconic Modern Homes in the WORLD!

(47:9)

The Theory of Interest | Jeffrey M. Herbener

(47:29)

Social Physics, Biophysics, Cycles and Signals (Jammed)

(2:39:9)

Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: ASCO GU 2023

(51:9)

Interesting Spine Case Discussion Series - Matt Colman, MD

(1:7:54)

New Mum Given Weeks to Live | Terminal Cervical Cancer

(3:33)

Clarke and Dawe - The Energy Market Explained

(2:37)

AMRITA online International Lecture series 2025

(1:29:39)

Renal Angiomyolipoma: Current Evidence and Advances in Management

(47:50)

Treating the Root Cause of Fatigue \u0026 PEM in Long Covid \u0026 ME/CFS: Mitodicure | With Prof. Klaus Wirth

(10:2)

The role of ICIs in the adjuvant setting for RCC

(53)

Dr. Matthew Zibelman on IO educational opportunities

(1:26)

Treatment Sequencing and Use of Biomarkers to Guide Treatment Selection in Bladder Cancer

(10:4)

How Do Prior Therapies in the Perioperative Space Inform Subsequent Treatment Selection?

(5:14)

Together Facing Bladder, Kidney and Prostate Cancers

(2:26:44)

Phase I/II study of nivolumab and axitinib for advanced RCC

(1:29)

Audrey Zibelman - Revolutionising the Energy Vision in New York

(30:11)

Panel Comments on Most Impactful Studies and Data in Bladder Cancer

(4:46)

Shining a Light on the Brain for Healing with Dr Michael Hamblin

(1:41:28)

What Are Treatment Options for Patients With Platinum-Ineligible Bladder Cancer?

(4:5)

Advancements in Bladder Cancer Research: A Conversation with Leading Experts

(1:20:9)

Treatment Considerations for Patients With Cisplatin-Ineligible Bladder Cancer

(13:25)

Finding the Right Medicine One Patient at a Time

(1:12:19)